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Abstract
Introduction. High sensitivity troponin T (TnT-hs) is biomarker of myocardial damage and ischemia. Despite its 
elevation troponin still preserve its usefulness as a marker of the cardiovascular risk and mortality in chronic kidney 
disease. Variations of hydration status between and during hemodialysis exert significant hemodynamic effects, which 
may negatively affect cardiovascular system and blood pressure and lead to myocardial damage. 
The aim of the study was to access the effect of hydration status and variability of blood pressure and heart rate 
induced by hemodialysis on intradialytic changes of TnT-hs, in chronic hemodialysis patients.
Material and methods. In 50 chronic hemodialysis patients (35M, 15F, mean age 64 ± 12 years) blood pressure and 
heart rate were monitored noninvasively during HD session. Serum concentration of TnT-hs and hydration status 
were assessed before and after hemodialysis. 
Results. TnT-hs concentration was above normal range in 98% patients before, and in all after hemodialysis. Median 
TnT-hs level was 82 ng/L before and 84 ng/L after hemodialysis, which comprised 586% and 600% of the upper 
limit of normal range. There was a small 2.4%, intradialytic increase of TnT-hs (p = 0.004). TnT-hs levels correlated 
positively with mean interdialytic weigh gain, before HD (r = 0.43, p = 0.02) and after HD (r = 0.5, p = 0.003). 
There was also a positive correlation between TnT-hs concentration and mean heart rate (r = 0.37, p = 0.008) and 
with mean systolic blood pressure during HD, before HD (r = 0.3, p = 0.026) and after HD (r = 0.3, p = 0.031). 
Conclusions. Hemodialysis can be a risk factor of myocardial injury, especially in overhydrated patients. 
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Streszczenie 
Wstęp. Wysokoczuła troponina T (TnT-hs) jest przydatnym klinicznie wskaźnikiem uszkodzenia komórek mięśnia 
sercowego. Stężenia TnT-hs u pacjentów z przewlekłą chorobą nerek są wyższe niż w populacji ogólnej, co wiąże się 
ze zwiększonym ryzykiem incydentów sercowo-naczyniowych oraz zgonu. Znaczne zmiany stopnia nawodnienia 
w czasie zabiegu hemodializy mogą niekorzystnie oddziaływać na układ sercowo-naczyniowy i ciśnienie tętnicze, co 
w efekcie może prowadzić do uszkodzenia kardiomiocytów. 
Celem pracy była ocena wpływu stanu nawodnienia, zmian częstości rytmu serca (HR) i ciśnienia tętniczego (BP) 
w trakcie hemodializy (HD) na zmiany stężeń TnT-hs powodowane zabiegiem hemodializy u pacjentów długotrwale 
hemodializowanych.
Materiał i metody. U 50 pacjentów (35M, 15K, średnia wieku 64 ± 12 lat) z rozpoznaniem schyłkowej niewydol-
ności nerek, długotrwale hemodializowanych, nieinwazyjnie monitorowano BP oraz HR podczas HD. Przed i po 
HD dokonano oceny stanu nawodnienia pacjenta oraz pobrano próbki krwi w celu oznaczenia stężenia TnT-hs.
Wyniki. Zwiększone stężenie w surowicy TnT-hs stwierdzono u 98% pacjentów przed zabiegiem HD oraz u 100% pacjen-
tów po zabiegu. Mediana TnT-hs wynosiła 82ng/l przed HD i 84 ng/l po zabiegu, co wyniosło odpowiednio 586% oraz 
600% wartości górnego zakresu referencyjnego. Stężenie TnT-hs podczas HD wzrastało nieznacznie o 2,4% (p = 0,04). 
Stężenie TnT-hs przed HD i po zabiegu korelowało ze średnim HR (r = 0,37; p = 0,008) oraz średnim skurczowym BP 
podczas zabiegu HD (przed HD r = 0,32; p = 0,026 i po HD r = 0,3; p = 0,031). Wykazano dodatnią korelację między 
przewodnieniem pomiędzy dializami a stężeniem TnT-hs przed HD (r = 0,43, p = 0,02) i po HD (r = 0,5, p = 0,003).
Wnioski. Zabieg hemodializy może zwiększać ryzyko uszkodzenia mięśnia sercowego, w szczególności w przypadku 
znacznego stopnia przewodnienia.
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Introduction
End-stage renal disease (ESRD) has been associat-
ed with a substantially reduced life expectancy [1]. 
The patients suffering from chronic kidney disease 
(CKD) have significantly higher cardiovascular 
and all-cause mortality compared to the general 
population. It is also known that the cardiovascu-
lar complications are the main cause of death in 
CKD population and the course of the cardiovas-
cular disease (CVD) and its progression with age 
is significantly accelerated [2]. The pathogenesis of 
cardiovascular disease in CKD is multifactorial, in-
cluding high prevalence of traditional risk factors 
such as hypertension, diabetes, atherogenic dyslipid-
emia and the factors specific to kidney disease, e.g., 
high concentration of uremic toxins, albuminuria, 
chronic inflammation, anemia and malnutrition, or 
calcium-phosphate disorders, arterial calcification, 
sodium and water overload, increased activity of 
the renin-angiotensin-aldosterone system and sym-
pathetic tone [3]. 
Troponins are valuable prognostic biomarkers of 
CVD risk and mortality [4]. In the general popula-
tion serum cardiac troponin levels are widely used to 
diagnose myocardial ischemia and damage. Cardiac 
troponin T (cTnT) and I  are myocardial proteins 
that form a  complex that plays a  physiologic role 
in the regulation of myocardial contraction. The 
isoforms of human troponin are encoded by speci-
fic genes, hence these markers are considered to be 
unique to the heart. Troponin complex is located 
intracellularly, thus increased blood concentration 
of these markers indicates the cardiac injury. How-
ever serum troponin levels in the patients with renal 
failure are permanently elevated even in the absence 
of ischemia. Since there is no clear explanation of 
this phenomenon the diagnosis of heart disease or 
acute coronary syndrome remains challenging in this 
group. The previous studies have indicated that the 
reduced renal clearance is the most likely but not the 
sole mechanism for troponin elevation in CKD. De-
spite its constant elevation troponin still holds a po-
tential as a marker of myocardial injury in CKD [5] 
and the troponins still preserve its usefulness as 
a marker of the cardiovascular risk and risk of short-
term mortality [6]. 
Hemodialysis (HD) therapy is a  life-sustaining 
procedure for the end-stage renal disease and is 
the most popular method of the renal replacement 
therapy. It involves toxin removal through molecule 
diffusion and fluid removal through ultrafiltration, 
however the specific schedule of this treatment and 
the variation of hydration status between and during 
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HD sessions exert significant hemodynamic effects, 
which may negatively affect cardiovascular system 
and blood pressure (BP). HD patients are charac-
terized by a particularly high prevalence of coronary 
arteries atherosclerotic changes, left ventricular hy-
pertrophy, arterial wall stiffness, reduced peripheral 
compliance, impaired microcirculation and ineffec-
tive vasoregulation, which may all predispose to re-
duced coronary reserve and cardiac ischemia. Addi-
tionally 20–30% of intermittent HD treatments are 
complicated by episodes of intradialytic hypotension 
(IDH). Hemodialysis procedure may also lead to 
myocardial stunning and hibernation [7]. All of 
these factors cumulate during hemodialysis that may 
lead to myocardial ischemia and injury, and thereby 
to cardiac troponin release. 
High sensitivity troponin T (TnT-hs) is a  bio-
marker that is widely measured to detect acute 
myocardial ischemia. Its assessment permits the 
detection of very low levels of TnT and may be 
particularly important in the patients with a short 
duration from symptom onset, but so far little has 
been known about the influence of a standard he-
modialysis procedure on high sensitivity troponin T 
concentrations. 
The aim of the study was to access the effects of 
hydration status, anemia, variations of blood pressure 
and heart rate induced by hemodialysis on intra-
dialytic changes of high sensitivity troponin T, in 
chronic hemodialysis patients. 
Material and methods
The study group included 50 patients (35 men and 
15 women, mean age 65 ± 12 years) with ESRD, 
treated by the intermittent hemodialysis using low-
flux dialyzers with Helixone membrane (Fx-class Low 
Flux Dialysers, Fresenius Medical Care, Bad Hom-
burg, Germany), 3 times per week, with short dialy-
sis vintage (median 7 months, range 3–45 months). 
72% of the patients were dialyzed through an arte-
rio-venous fistula and 38% through a central venous 
catheter. The mean single hemodialysis session lasted 
3 hours and 39 minutes with standard deviation (SD) 
22 minutes. The causes of ESRD in study group were 
diabetic nephropathy 26% (n = 13), chronic glomer-
ulonephritis 16% (n = 8), hypertensive nephropathy 
10% (n = 5), polycystic kidney disease 10% (n = 5), 
nephrolithiasis 8% (n = 4), urosepsis 2% (n = 1) and 
unestablished etiology 28% (n = 14). Ischemic heart 
disease had been diagnosed before the onset of the 
study in 40% of patients and chronic heart failure in 
24%. Thirty six percent of individuals in the study 
group were diabetic. Basic characteristics of the study 
group are shown in table I. 
All study procedures were performed during the 
second dialysis session of the week (mid-week dia-
lysis). The chest pain or other symptoms suggesting 
acute coronary syndrome or exacerbation of chronic 
heart failure (CHF) as well as infections or other 
acute illnesses, were the exclusion criteria. 
Blood sampling was performed at two time-
points: directly before the dialysis session (predia-
lysis sample) and after the prescribed dialysis time 
was completed (postdialysis sample). The blood 
samples were collected for the measurement of the 
serum concentration of TnT-hs, NT-proBNP, urea, 
albumin and full blood count. For the additional 
calculations all postdialysis values of TnT-hs and 
NT-proBNP were adjusted for the changes in their 
concentration caused by hemoconcentration, caused 
by ultrafiltration, using formula [8]: 
Adjusted TnT-hs formula =     
current TnT-hs after HD
                                               serum albumin after/before HD
The hydration status was assessed by bioimpedance 
spectroscopy (Body Composition Monitor, Fresenius 
Medical Care AG & Co, Bad Homburg, Germany), 
which involves placing 4 electrodes one on each ex-
tremity. The result taken for analysis was an arithmetic 
mean of three consecutive measurements. Overhydra-
tion grade was calculated using the following formula: 
Table I. Clinical characteristics of the study group
Subjects (n = 50)
Age (years) 65 ± 12
Sex Male 70% (n = 35)
Female 30% (n = 15)
Dialysis vintage (months) Median 7
Min. 3, max. 45 
Time of each HD session 3h 39 min. ± 22 min. 
Vascular access through HD catheter 25% (n = 14)
Vascular access through  
arterio-venous fistula 
75% (n = 36)
Ischemic Heart Disease 40% (n = 20)
Diabetes Mellitus 36% (n = 18)
Atrial Fibrillation 14% (n = 7)
Chronic heart failure 24% (n = 12)
Hemoglobin (HGB) (g/dL) 10.7 ± 1.5
HGB < 10 g/dL 26% (n = 13)
HGB ≥ 10 g/dL 74% (n = 37)
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Figure 1. Serum concentrations of TnT-hs before and after hemo-
dialysis
Figure 2. Intradialytic changes of TnT-hs serum concentration
hydration (%)
  Grade of over- =  
overhydration befor HD [kg]
                                      dry weight [kg]
Additionally the information about the mean in-
tradialytic weight gains and dry weight were collected 
from 2 months prior data acquisition and were used 
to calculate the percentage interdialytic weight gain. 
Blood pressure and heart rate were monitored 
noninvasively, by BR-102 plus ABPM system (Schil-
ler, Warsaw, Poland sp. z o.o.), during all hemodi-
alysis procedure. The monitors cuff was placed on 
the non-dominant arm of the patient or, in case of 
patients dialyzed through an arterio-venous fistula, 
on the opposite arm. For the precise measurements 
cuff size was adjusted individually. The device record-
ed the readings of blood pressure and heart rate each 
15 minutes, which resulted in up to 21 readings for 
a single hemodialysis session. Echocardiography was 
performed by one experienced echocardiographist on 
36 patients of 50, within 2 hours after hemodialysis 
(Vivid q, GE Healthcare, Wauwatosa, USA). 
The statistical calculations were performed with 
the Statistica 13.1 software (StatSoft Poland, Cra-
cow, Poland). Shapiro-Wilk test was used to check 
the normality of data and non-parametric tests: 
Mann-Whitney U test for independent samples and 
Wilcoxon signed rank test for paired samples. Cor-
relations were calculated using Spearman’s formula. 
Results
High sensitivity serum cardiac troponin T concen-
tration was above normal range in 98% patients be-
fore hemodialysis and in all patients after hemodialysis 
compared to the upper limit of reference range for the 
general population. Predialysis values of TnT-hs ranged 
from 14 to 255 ng/L and postdialysis from 16 to 234 
ng/L. Median TnT-hs level accounted for 82 ng/L be-
fore and 84 ng/L after hemodialysis, which comprises 
586% and 600% of the upper limit of normal range, 
respectively (Figure 1). The increase of TnT-hs induced 
by the hemodialysis procedure in whole study group 
was small — about 2.4%, but statistically significant 
(p = 0.004) (Figure 2). The high sensitivity troponin 
T levels correlated positively with overhydration status 
before a  single hemodialysis procedure measured by 
body composition monitor both before (r = 0.31, p 
= 0.03) and after HD (r = 0.28, p = 0.055). TnT-hs 
correlated also with mean interdialytic weigh gain in 
two months before the study before HD (r = 0.43, p 
= 0.02) and after HD (r = 0.5, p = 0.003) (Figure 3). 
There was a positive correlation between TnT-hs con-
centration and mean heart rate before HD (r = 0.37, 
p = 0.008) and after HD (r = 0.37, p = 0.0087) (Figure 4), 
and with the mean systolic blood pressure during HD 
before HD (r = 0.3, p = 0.026) and after HD (r = 0.3, 
p = 0.031) (Figure 5). There was no statistically signifi-
cant correlation between blood pressure and heart rate 
standard deviation with TnT-hs levels.
There was a  negative correlation of TnT-hs before 
dialysis and hemoglobin (r = –0.28, p = 0.047). Patients 
with a  hemoglobin level below 10 g/dL have signifi-
cantly higher TnT-hs concentration compared to in-
dividuals with hemoglobin level above 10 g/dL, before 
HD: 107 vs. 73 ng/L (p = 0.013) and after HD 106.9 
vs 79 ng/L (p = 0.015), respectively. TnT-hs concentra-
tions did not change significantly during HD in anemic 
× 100%
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Figure 4.Correlation between heart rate during HD session and 
TnT-hs levels
Figure 5. Correlation between mean SBP during HD session and 
TnT-hs levels
Figure 3. Correlation between interdialytic weigh gain and TnT-hs concentrations
patients, moreover the increase of high sensitivity tro-
ponin T was revealed in those with hemoglobin level 
above 11 g/dL — from 70 to 75 ng/L (p = 0.014). In 
the subgroup of patients with diabetes the tendency to 
higher TnT-hs levels was noted, as shown in Figure 6. 
Predialysis, postdialysis levels and intradialytic changes 
of ThT-hs were similar in patients with and without 
ischemic heart disease and the same applied to chronic 
heart failure. High sensitivity troponin T concentrations 
correlated positively with left ventricle mass (r = 0.43; 
p = 0.01). Besides the intradialytic increase of TnT-hs in 
the patients with decreased left ventricle ejection fraction 
LVEF < 50% was 2.7 ng/L while in those with LVEF 
> 50% was much lower 0.8 ng/L (p = 0.02) (Figure 7).
Discussion
Serum troponin assays are widely used in patients 
with ESRD undergoing hemodialysis despite the 
unspecific increase of their serum concentration. 
That was also seen in our patients since almost all 
of the study subjects had elevated levels of TnT-hs 
both pre- and post-dialysis. In one previous study 
of Mbagayasa et al, designed to evaluate a biological 
variation of cardiac troponin in stable HD patients, 
new-generation, serum high sensitivity troponin T 
was elevated in almost all patients, whereas tropo-
nin I was above normal range in only 30% of HD 
patients [9]. The mechanisms underlying troponin 
release in CKD include direct myocardial damage 
from circulating uremic endotoxins and an adverse 
metabolic milieu, subclinical epicardial or microvas-
cular coronary artery disease (CAD) and heart failure, 
“demand” ischemia secondary to volume shifts and 
hemodynamic stressors during HD [10]. Multivessel 
CAD is often seen in angiographic studies of asymp-
tomatic HD patients [11]. In contrast to what we 
have expected, cTnT-hs levels in our study group 
did not significantly differ in the individuals with or 
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Figure 7. Intradialytic increase of TnT-hs in patients with decreased LVEF
Figure 6. TnT-hs serum concentrations before and after HD in diabetic patients
without a cardiovascular disease history. The possible 
reason may be the underdiagnosis of CAD in our 
ESRD population. The concentration of cardiac high 
sensitivity troponin T correlated with left ventricle 
mass in our study that could be a  consequence of 
a higher number of cardiomyocytes where this mark-
er is stored and released from. In the patients with 
chronic kidney disease, the prevalence of left ventri-
cular hypertrophy is strikingly increased that in par-
ticular applies to concentric hypertrophy. About 50% 
of the patients with an estimated glomerular filtration 
rate (eGFR) lower than 30 ml/min/1.73 m2 develops 
left-ventricular hypertrophy [12]. Factors such as re-
duced coronary reserve in chronic kidney disease and 
reduced cardiac capillary density in the thick cardiac 
muscle, could make large left ventricle muscle more 
susceptible to short episodes of ischemia and damage, 
as a consequences of hemodynamic changes during 
hemodialysis procedure, and more massive release of 
such cardiac biomarkers as troponins T. 
The subgroup of hemodialyzed patients, in which 
we found a tendency to higher cardiac high sensitivity 
troponin T concentrations, were the patients with 
diabetes. In addition to high prevalence of coronary 
atherosclerosis, diabetic patients on hemodialysis have 
been shown to have a reduced coronary flow reserve 
even in the absence of coronary vessel lesions [13], 
what may predispose them to myocardial ischemia. 
In our study we noted a small but a significant in-
crease of the concentration of high sensitivity cardiac 
troponin T after a hemodialysis session. A diagnosis 
of myocardial infarction requires larger changes and 
the presence of symptoms and/or changes in ECG. 
However, even small increases might be associa - 
ted with major adverse cardiac events in the further 
course of the disease, as shown in a  post-surgery 
study [14]. 
Most previous studies of cardiac biomarkers in 
ESRD present conflicting results [15–19]. Postdi-
alysis values increased, decreased or remained stable 
compared to predialysis concentrations. In most of 
the studies however older generation of troponin 
I and T assays were used, which levels become eleva-
ted only after 6 to 12 hours after the episode of is - 
chemia. This is beyond the window of blood sampling 
in most of the currently available studies. TnT-hs as-
says seem to be more useful for that purpose as they 
detect smaller amounts of troponins and in shorter 
time after the event. Other factors could be also im-
portant, as a type of dialysis membrane used for the 
procedure. Sommerer et al. measured cTnT levels in 
49 chronic hemodialyzed patients before and after 
HD session by a third generation assay [20]. Level of 
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cTnT increased significantly after a hemodialysis in 
which low-flux (LF) dialyzer was used, but remained 
unchanged when high-flux (HF) dialyzer was uti-
lized. A main reason for the stable levels of cardiac 
markers in that study [20], or a reduction reported 
by others [8], is that the approximate 97% cutoff 
level of high flux dialyzers was i.e. 40 kDa, while 
for the low flux dialyzers cutoff was much lower, i.e. 
6 kDa. The molecular weight of NT-proBNP is 
8.5 kDa and troponin T 37 kDa and its fragments 
ranging in size from 8 to 25 kDa, so they can be easi-
ly removed during HF-HD procedure. The elevation 
of TnT during hemodialysis using low flux dialyzer, 
was in the authors’ opinion partly due to hemocon-
centration. In our observation, where the low flux 
membranes were used, the significant increase of 
TnT-hs was seen even after the correction for the 
effect of hemoconcentration, induced by withdrawal 
of fluid during dialysis. Similar results were obtained 
by Laveborn et al., who studied the change of cardiac 
biomarkers TnT-hs and NT-proBNP in 31 hemo-
dialyzed patients after hemodialysis with high and 
low flux dialyzer. They noted, that during LF-HD 
the TnT-hs level increased from 95 to 101 ng/L 
(p = 0.001), whereas during HF-HD decreased from 
84 to 70 ng/L (p = 0.003) [8]. The significant in-
crease in TnT-hs during low-flux HD strongly indi-
cates that the dialysis session may induce a potential-
ly detrimental effect on the myocardium. The limited 
increase of TnT-hs after hemodialysis can reflect the 
myocardial damage but could also be a sign of a re-
duced myocardial blood flow or myocardial stunning 
during HD. The evidence of HD-induced myocar-
dial ischemia came from electrocardiogram-based 
studies and isotopic perfusion imaging. Zuber et al. 
demonstrated silent ST-depression occurring during 
hemodialysis [21] and its rates varied between 15 to 
40% in next studies [22–24]. Singh et al. observed 
the dialysis-induced myocardial perfusion defects in 
seven of ten patients, examined by single-photon 
emission computed tomography [25]. Another rea-
son for the increase of the cardiac markers could be 
the exposure to coronary microemboli that are often 
present during HD because of the leakage of small 
air bubbles into the blood drains [26]. The capabi-
lity of hemodialysis to induce subclinical myocardial 
ischemia could be related also to high ultrafiltra-
tion rate and hemodynamic instability. HD-induced 
myocardial stunning was identified in around 60% 
of 70 HD-patients studied with serial intradialytic 
echocardiography by Burton et al. [27]. In a mul-
tivariate analysis intradialytic reduction in BP and 
ultrafiltration volume were independent risk factors 
of heart injury. Selby and McIntyre also found that 
the ultrafiltration volumes were a risk factor for the 
development of myocardial stunning during dialysis 
[28]. In our analysis the fluid retained in the body 
between dialyses, that was reflected by the interdia-
lytic weigh gain and overhydration status of patient 
before single HD procedure correlated positively 
with a predialysis cTnT-hs. What is interesting, we 
found that the patients with a decreased LVEF were 
particularly prone to cardiac damage during dialysis, 
because of higher elevation of TnT-hs during HD 
compared to those with LVEF > 50%. Such patients, 
besides general ill condition of the heart, are usually 
more overhydrated due to heart failure, what could 
be an additional risk factor of HD-induced cardi-
ac stunning. Other candidate risk factor of chronic 
cardiac ischemia recognized in our study was a he-
moglobin level below 10 g/dL, but the patients with 
hemoglobin values above 11 g/dL could be also pre-
disposed to the acute myocardial ischemia during 
HD. TnT-hs in this group increased significantly 
by 5% during HD. It could be speculated that the 
hemoconcentration in such patients could predispose 
them to thrombosis and coronary arteries occlusion. 
It is generally recognized, that there has been no ad-
ditional cardiovascular benefit from the correction of 
hemoglobin concentrations to above 12 g/dL. 
The importance of the hemodynamic stability in 
the pathogenesis of HD-induced ischemic injury was 
illustrated in the studies that investigated the mo-
dification of dialysis technique to maintain adequate 
blood pressure [28]. Higher mean blood pressure 
and a reduction of intradialytic hypotension (IDH) 
episodes improved myocardial perfusion [29]. How-
ever in our study the levels of TnT-hs in the patients 
with IDH were similar to those in patients with 
optimal blood pressure control. Previous studies also 
showed that the local and global myocardial blood flow 
decreased during hemodialysis, independently from 
a  concurrent level of systemic blood pressure [30]. 
We noticed a  positive correlation of TnT-hs with 
systolic blood pressure and heart rate, suggesting 
that high blood pressure and fast heart rate might 
be also harmful. The correlation of TnT-hs with 
systolic blood pressure may be rather the result of 
a higher prevalence of left ventricle hypertrophy in 
patients with hypertension. Coronary blood flow 
takes place mostly during diastole, and the driving 
pressure gradient is the difference between mean dia-
stolic pressure in the aortic root and mean right atrial 
pressure. Both the driving pressure gradient and the 
duration of diastole are the essential mechanical de-
terminants of coronary blood flow [31]. That is why 
any factor that decreases the diastolic pressure-time 
integral will also decrease coronary blood flow, that 
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is, any decrease in diastolic aortic root pressure, any 
increase in right/left ventricular diastolic pressure, 
which may be caused be sudden changes of systemic 
blood pressure or any reduction in diastolic dura-
tion, which happens in acceleration of heart rate, 
will decrease coronary blood flow and can exacerbate 
ischemia during hemodialysis and thereby lead to 
troponin release. 
In summary, the identification of clinical manifes-
tations of cardiovascular disease, in particular isch-
emic heart disease, is challenging in patients with 
chronic kidney disease. Many patients with ESRD 
are asymptomatic or develop atypical manifestations 
despite a major acute ischemic event. Clinicians must 
be fully aware of this fact to avoid underdiagnoses 
of potentially life-threatening cardiovascular events. 
This is particularly relevant in hemodialyzed patients, 
who have notably worse prognoses. Chronically ele-
vated troponins are frequent source of clinical un-
certainty in this population. The knowledge about 
increased concentrations of cardiac high sensitivity 
troponin T and influencing factors, including he-
modialysis procedure, is crucial for the identification 
which group of ESRD patients and in which clinical 
situation is at particular high risk of acute cardiovas-
cular event. 
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